IRIS
TRAVELLI, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 364
EU - Europa 227
AS - Asia 75
OC - Oceania 2
Totale 668
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 364
IE - Irlanda 123
IT - Italia 48
SG - Singapore 46
CN - Cina 27
FI - Finlandia 23
DE - Germania 19
BE - Belgio 9
AU - Australia 2
NL - Olanda 2
GB - Regno Unito 1
RU - Federazione Russa 1
SE - Svezia 1
TR - Turchia 1
TW - Taiwan 1
Totale 668
Salva come PNG Salva come JPEG
Città #
Dublin 123
Chandler 113
Ashburn 43
Boardman 41
Helsinki 23
Shanghai 19
Singapore 17
Ann Arbor 15
Lawrence 15
Princeton 15
Medford 11
Bolzaneto 9
Brussels 9
Wilmington 9
Falkenstein 8
Milan 7
Chicago 6
Bossico 4
Council Bluffs 4
New York 4
Norwalk 4
Nuremberg 4
Washington 4
Munich 3
Turin 3
Barbianello 2
Des Moines 2
Treviglio 2
Adelaide 1
Cambridge 1
Dallas 1
Foshan 1
Guangzhou 1
Huizhou 1
Kaifeng 1
Los Angeles 1
Moscow 1
Pinerolo 1
Rome 1
San Francisco 1
Seattle 1
Sydney 1
Taipei 1
Trezzano sul Naviglio 1
Totale 535
Salva come PNG Salva come JPEG
Nome #
OXER1 and RACK1-associated pathway: a promising drug target for breast cancer progression 56
Ribosomes as a nexus between translation and cancer progression: Focus on ribosomal Receptor for Activated C Kinase 1 (RACK1) in breast cancer 45
Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis 43
Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is a tumoural cytokine released from melanoma 43
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity 40
Nicotinamide phosphoribosyltransferase acts as a metabolic gate for mobilization of myeloid-derived suppressor cells 39
Data on metabolic stability, aqueous solubility and CYP inhibition of novel triazole-based nicotinamide phosphoribosyltransferase (NAMPT) inhibitors 39
Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity 38
A nicotinamide phosphoribosyltransferase–GAPDH interaction sustains the stress-induced NMN/NAD+ salvage pathway in the nucleus 37
The Cytokine Nicotinamide Phosphoribosyltransferase (eNAMPT; PBEF; Visfatin) Acts as a Natural Antagonist of C-C Chemokine Receptor Type 5 (CCR5) 34
Design, synthesis, and biological evaluation of combretabenzodiazepines: A novel class of anti-tubulin agents 34
Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group 31
Prostaglandin E2 and cancer: Insight into tumor progression and immunity 29
Mucosal Overexpression of Thymic Stromal Lymphopoietin and Proinflammatory Cytokines in Patients With Autoimmune Atrophic Gastritis 27
Molecular characterization of membrane steroid receptors in hormone-sensitive cancers 26
Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy 23
Molecular regulations of circadian rhythm and implications for physiology and diseases 22
NAMPT: A pleiotropic modulator of monocytes and macrophages 18
Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis 16
Disruption of epithelial barrier integrity via altered GILZ/c-Rel/RACK1 signaling in inflammatory bowel disease (IBD) 10
A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry 9
Pro- and anti-inflammatory cytokines: the hidden keys to autoimmune gastritis therapy 8
Involvement of eNAMPT/TLR4 inflammatory signaling in progression of non-alcoholic fatty liver disease, steatohepatitis, and fibrosis 6
The NAMPT inhibitor FK866 reverts the damage in spinal cord injury 6
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer 6
Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors 6
Extracellular nicotinamide phosphoribosyltransferase boosts IFNγ-induced macrophage polarization independently of TLR4 5
eNAMPT/TLR4 inflammatory cascade activation is a key contributor to SLE Lung vasculitis and alveolar hemorrhage 5
Autophagy and inflammation an intricate affair in the management of obesity and metabolic disorders: evidence for novel pharmacological strategies? 5
Identification of a novel NAMPT inhibitor by combinatorial click chemistry and chemical refinement 5
Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine 5
Insight Into Nicotinamide Adenine Dinucleotide Homeostasis as a Targetable Metabolic Pathway in Colorectal Cancer 5
Targeting Transient Receptor Potential Vanilloid 1 (TRPV1) Channel Softly: The Discovery of Passerini Adducts as a Topical Treatment for Inflammatory Skin Disorders 5
Identification of novel aza-analogs of TN-16 as disrupters of microtubule dynamics through a multicomponent reaction 5
Metabolic regulation of suppressive myeloid cells in cancer 4
Synthesis and Degradation of Adenosine 5′-Tetraphosphate by Nicotinamide and Nicotinate Phosphoribosyltransferases 4
Triazole-curcuminoids: A new class of derivatives for 'tuning' curcumin bioactivities? 4
Characterization of NAD uptake in mammalian cells 4
NAD depletion by FK866 induces autophagy 4
NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel disease 3
Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions 3
Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells 3
Totale 760
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.673
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.673
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202119 0 0 0 0 0 0 11 0 6 0 1 1
2021/202297 1 1 1 0 2 1 0 7 5 1 10 68
2022/2023317 17 34 15 22 22 34 0 18 143 2 8 2
2023/2024108 9 13 6 11 17 29 0 20 1 1 0 1
2024/2025219 38 45 10 49 2 48 27 0 0 0 0 0
Totale 760